| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |